Skip to main content
. 2019 Mar 28;70(3):436–445. doi: 10.1093/cid/ciz254

Figure 2.

Figure 2.

Willingness of multidrug-resistant tuberculosis (MDR-TB)/rifampicin-resistant tuberculosis (RR-TB) household contacts to take newly developed MDR-TB preventive therapy, stratified by clinical research site (left panel). Number of enrolled MDR-TB/RR-TB household contacts at each clinical research site (right panel).